2-Bromo-?-ergocryptine
Eating Behavior
University of North Carolina, Chapel HillSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Eating Behavior cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide University Hospital Sestre Milosrdnice | Phase 4 | BB |
Rimonabant Sanofi | Phase 3 | CC |
PYY(3-36) Gila Therapeutics, Inc. | Phase 1 | CC |
Octreotide Pamoate St. James's Hospital, Ireland | D | |
GLUCAGON-LIKE PEPTIDE 1, HUMAN Haukeland University Hospital | D |
View all 10 →
Same molecule, other indications
2-Bromo-?-ergocryptine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →